SUMMARY
Strong record of directing a diverse and productive research program in biochemistry, biologics drug discovery, and molecular biology. Specific expertise includes protein evolution/engineering, intracellular biologics delivery, nanobody- based immunotherapeutic discovery, RNA-targeted protein and peptide drug discovery, protein-based cancer imaging, antiviral entry inhibitor discovery, synthetic organic chemistry and biocatalysis / artificial metalloenzyme discovery and optimization. Strong record of teaching undergraduate and graduate level chemistry, chemical biology, and biological sciences courses. Recipient of college-wide award for teaching and mentoring at the undergraduate level.
EXPERIENCE
DELAWARE STATE UNIVERSITY – 2020- CURRENT
§ Senior Fellow – Delaware Institute for Science & Technology
§ Adjunct Professor – Department of Biological Sciences
COLORADO STATE UNIVERSITY – 2015-18
§ Associate Professor of Chemistry (primary affiliation)
§ Associate Professor of Biochemistry & Molecular Biology (secondary affiliation)
COLORADO STATE UNIVERSITY – 2009-15
§ Assistant Professor of Chemistry (primary affiliation)
§ Assistant Professor of Biochemistry & Molecular Biology (secondary affiliation)
HARVARD UNIVERSITY – 2007-09
§ Postdoctoral Fellow, Advisor: Professor David R. Liu
UNIVERSITY OF ROCHESTER – 2002-07
§ Graduate Student, Advisor: Professor Benjamin L. Miller
EDUCATION
UNIVERSITY OF ROCHESTER
2002-2007
Doctor of Philosophy, Chemistry (Chemical Biology)
INDIANA UNIVERSITY OF PENNSYLVANIA
1996-2000
Bachelor of Science, Chemistry
TEACHING
▪ CHEM 341: Modern Organic Chemistry I (CSU) ▪ BIOL 420: Immunology (DSU)
▪ CHEM 543: Physical Organic Chemistry (CSU) ▪ BIOL 215: Cell Biology Laboratory (DSU)
▪ CHEM 521: Principles of Chemical Biology (CSU) ▪ BIOL 415: Pharmacology (DSU)
▪ CHEM 523: Methods in Chemical Biology (CSU) ▪ BIOL 310: Molecular Biology (DSU)
▪ BIOL 101: General Biology (DSU)
PUBLICATIONS
As principal investigator – *corresponding author; (undergraduate co-author)
1. WZ Charles, CR Fairies, YT Street, AD Wilson, DW Crawford, PC Beardslee, A Hendrickson, BR
McNaughton* “Cell Surface β-Lactamase Recruitment as a Selection Platform to Identify Macromolecular
Interactions” (in preparation)
2. I Hassan, J Fuller, V Dippon, AN Ta, MW Dannerman, BR McNaughton*, A Alexandrova*, T Rovis* “Tuning
Through-Space Interactions via the Secondary Coordination Sphere of an Artificial Metalloenzyme Leads to
Enhanced Rh(III)-Catalysis” Chemical Science, 13, 9220 (2022)
3. WZ Charles, CR Faries, YT Street, LS Flowers BR McNaughton* “Antibody Recruitment as a Therapeutic
Strategy: A Brief History and Recent Advances” ChemBioChem, 23, e202200092 (2022)
4. PA Rosario, BR McNaughton* “Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding
Domain / ACE2 Complex” ChemBioChem, 22, 1196 (2021)
5. AN Ta, RL Tennyson, DC Aceveda, BR McNaughton* “Disparities Between Antibody Occupancy, Orientation,
and Cytoxicity in Immunotherapy” ChemBioChem, 21, 2435 (2020)
6. T Ikeda, RL Tennyson, SN Walker, RS Harris, BR McNaughton* “Evolved Proteins Inhibit Entry of
Enfuvirtide-Resistant HIV-1” ACS Infectious Diseases, 5, 634 (2019)
7. IS Hassan, AN Ta, MW Danneman, N Semakul, M. Burns, CH Basch, VN Dippon, BR McNaughton*, T Rovis*
“Asymmetric δ-Lactam Synthesis with a Monomeric Streptavidin Artificial Metalloenzyme” J. Am. Chem. Soc.,
141, 4815 (2019)
8. J Jenkins, DW Crawford, CE Cavender, DH Mathews, BR McNaughton*, JE Wedekind* “Structure of HIV TAR
in Complex with a Lab-Evolved RRM Provides Insight into Duplex RNA Recognition and Synthesis of a
Constrained Peptide that Impairs Transcription” Nucleic Acids Research, 45, 6401 (2018)
9. JN Bjerke, PC Beardslee, BR McNaughton* “Recent Advances in CRISPR Base Editing: From A to RNA”
Biochemistry, 57, 6, 886 (2018)
10. KG Nottingham, A McNally*, BR McNaughton* “Synthesis of Biotinylated Diazinon: Lessons Learned for
Biotinylation of Thiphosphate Esters” Tetrahedron Letters, 59, 234 (2018)
11. SN Walker, RL Tennyson, T Ikeda, RS Harris, BR McNaughton* “Evaluation of Sequence Variability in HIV-1
gp41 C-peptide Helix-Grafted Proteins” Bioorganic & Medicinal Chemistry, 26, 1220 (2018)
12. VJ Bruce, BR McNaughton* “Inside Job: Methods for Delivering Exogenous Proteins to Mammalian Cells” Cell
Chemical Biology, 24, 924 (2017)
13. Z Zhou, G Vaidyanathan, D McDonald, C Mo Kang, I Balyasnikova, N Devoogdt, AN Ta, BR McNaughton, M
Zalutsky* “Fluorine-18 Labeling of the HER2-Targeting Sncle-Domain Antibody 2RS15d Using a Residualizing
Label and Preclinical Evaluation” Molecular Imaging and Biology, 19, 867 (2017)
14. AN Ta, BR McNaughton* “Antibody and Antibody Mimetic Immunotherapeutics” Future Medicinal Chemistry,
9, 1301 (2017)
15. VJ Bruce, BR McNaughton* “Analysis of Nanobody-Conjugates and Protein Fusions as Bioanalytical
Reagents” Analytical Chemistry, 89, 3819 (2017)
16. VJ Bruce, AN Ta, BR McNaughton* “Minimalist Antibodies and Mimetics: An Update and Recent
Applications” ChemBioChem, 17, 1892 (2016)
17. RL Tennyson, SN Walker, T Ikeda, RS Harris, AJ Kennan*, BR McNaughton* “Helix-Grafted Pleckstrin
Homology Domains Suppress HIV-1 Infection of CD4-Positive Cells” ChemBioChem, 17, 1945 (2016)
18. DW Crawford, BD Blakeley, P-H Chen, C Sherpa, SFJ Le Grice, IA Laird-Offringa, BR McNaughton* “An
Evolved RNA Recognition Motif That Suppresses Tat/TAR-Dependent Transcription” ACS Chemical Biology, 8,
2206 (2016)
19. AM Chapman, BR McNaughton* “Scratching the Surface: Resurfacing Proteins to Endow New Properties and
Function” Cell Chemical Biology, 23, 543 (2016)
20. VJ Bruce, M Lopez-Islas, BR McNaughton* “Resurfaced Cell-Penetrating Nanobodies: A Potentially General
Solution for Intracellularly Targeted Protein Drug Discovery” Protein Science, 25, 1129 (2016)
21. MA Gray, RN Tao, SM DePorter, DA Spiegel, BR McNaughton* “Nanobody Activation Immunotherapeutics
That Selectively Destroys HER2-Positive Breast Cancer Cells” ChemBioChem, 17, 155 (2016)
22. AM Chapman, BR McNaughton* “Synthetic Proteins That Bind the Oncoprotein Gankyrin, Disrupt Its
Interaction with S6 ATPase, and Suppress MDM2/Gankyrin-Dependent Polyubiquitination of p53” ACS
Chemical Biology, 10, 1880 (2015)
23. SN Walker, AM Chapman, RL Tennyson, AJ Kennan*, BR McNaughton* “GLUE That Sticks to HIV: A Helix-
Grafted GLUE Protein That Potently and Selectively Binds HIV gp41 N-terminal Helical Region” ChemBioChem,16, 219 (2015)
24. AM Chapman, BE Rogers, BR McNaughton* “Characterization of the Binding Interaction Between the
Oncoprotein Gankyrin and Grafted S6 ATPase” Biochemistry, 53, 6857 (2014)
25. AM Chapman, BR McNaughton* “A Synthetic Protein that Binds the Oncoprotein Gankyrin and Inhibits
Gankyrin-Dependent Oncogenic Cellular Events” ACS Chemical Biology, 9, 2223 (2014)
26. SM DePorter, BR McNaughton* “Engineered Bacteriophage as Nanocarriers for the Delivery of Exogenous
Imaging Proteins and Enzymes to Human Prostate Cancer Cells” Bioconjugate Chemistry, 25, 1620 (2014)
27. U Mohan, R Burai, BR McNaughton* “Reactivity Between Acetone and Single-Stranded DNA Containing a 5¢-
Capped 2¢-Fluoro-N7-Methyl Guanine” Tetrahedron Letters, 55, 3358 (2014)
28. BD Blakeley, BR McNaughton* “Synthetic RNA Recognition Motifs that Selectively Bind HIV-1 Trans-
Activation Response Element Hairpin RNA” ACS Chemical Biology, 9, 1320 (2014)
29. SM DePorter, I Lui, VJ Bruce, MA Gray, M Lopez-Islas, BR McNaughton* “Mutational Effects Modulate the
Efficiency, Cell-Selectivity, and Functional Enzyme Delivery of a Protein Transduction Domain” Molecular
BioSystems 4, 10 (2014).
30. BD Blakeley, J Shattuck, MB Coates, E Tran, I Laird-Offringa, BR McNaughton* “Analysis of Protein/RNA
Complexes Involving an RNA Recognition Motif Engineered to Bind Hairpins with 7- and 8-Nucleotide
Loops” Biochemistry 52, 4754 (2013).
31. U Mohan, R Burai, BR McNaughton* “In Vitro Evolution of a Friedel-Crafts Deoxyribozyme” Organic &
Biomolecular Chemistry 11, 2241 (2013)
32. SM DePorter, I Lui, U Mohan, BR McNaughton* “A Protein Transduction Domain with Cell Uptake and
Selectivity Profiles that are Controlled by Multivalency Effects” Chemistry & Biology 20, 434 (2013).
33. SM DePorter, NK Hendricks, MA Gray, BR McNaughton* “A One-Pot Synthesis of Micron-sized and
Nanoscale poly(N-acryloxysuccinimide-co-N-vinylpyrrolidone) particles” Tetrahedron Letters 53, 6436 (2012)
34. SM DePorter, I Lui, BR McNaughton* “Programmed Cell Adhesion and Growth on Cell-Imprinted
Polyacrylamide Hydrogels” Soft Matter 8, 10403 (2012)
35. BD Blakeley, SM DePorter, U Mohan, R Burai, BS Tolbert, BR McNaughton* “Methods for Identifying and
Characterizing Interactions Involving RNA” Tetrahedron 68, 8837 (2012)
36. BD Blakeley, AM Chapman, BR McNaughton* “Split-Superpositive GFP Reassembly is a Fast, Efficient, and
Robust Methods for Detecting Protein-Protein Interactions In Vivo” Mol. BioSystems 8, 2036 (2012).
37. R Burai, J Chatwichien, BR McNaughton* “A Programmable Build – Couple Approach to the Synthesis of
Heterofunctionalized Polyvalent Molecules” Organic & Biomolecular Chemistry 9, 5056 (2011)
Harvard University (postdoctoral studies)
38. JJ Cronican, DB Thompson, KT Beier, BR McNaughton, CL Cepko, DR Liu “Potent Delivery of Functional
Proteins into Mammalian Cells In Vitro and In Vivo Using a Supercharged Protein” ACS Chemical Biology 5, 747
(2010)
39. BR McNaughton, JJ Cronican, DB Thompson, DR Liu “Mammalian Cell Penetration, siRNA Transfection, and
DNA Transfection by Supercharged Proteins” Proc. Natl. Acad. Sci, USA 106, 6111 (2009)
40. MR Rozenman, BR McNaughton, DR Liu “Solving Chemical Problems Through the Application of
Evolutionary Principles” Curr. Opin. Chem. Biol. 11, 259 (2008)
University of Rochester (graduate studies)
41. BR McNaughton, PC Gareiss, SE Jacobs, AF Fricke, GA Scott, BL Miller “A Potent Activator of Melanogenesis
Identified from Small Molecule Screening” ChemMedChem 4, 1583 (2009)
42. PC Gareiss, K Sobczak, BR McNaughton, PB Palde, CA Thornton, BL Miller “Dynamic Combinatorial Selection
of Small Molecules Capable of Inhibiting the (CUG) Repeat RNA–MBNL1 Interaction in vitro: Discovery of
Lead Compounds Targeting Myotonic Dystrophy (DM1)” J. Am. Chem. Soc. 130, 16254 (2008)
43. BR McNaughton, BL Miller “A Facile Synthesis of 2-Ethyl-Quinoline-3-Carboxylic Acid Hydrochloride” Org.
Synth. 85, 27 (2008)
44. BR McNaughton, PC Gareiss, BL Miller “Identification of a High-Affinity and Selective Ligand for the HIV-1
Frameshift-Inducing RNA Stemloop from an 11,325 Member Resin-Bound Dynamic Combinatorial Library” J.
Am. Chem. Soc. 129, 11306 (2007)
45. P Palde, BR McNaughton, NT Ross, PC Gareiss, CR Mace, RC Spitale, BL Miller “Single-Step Synthesis of
Functional Organic Receptors via a Tri-directional Minisci Reaction” Synthesis 15, 2287 (2007)
46. BR McNaughton, BL Miller “Resin-Bound Dynamic Combinatorial Chemistry” Org. Lett. 8, 1803 (2006)
47. BR McNaughton, KM Bucholtz, Moure, AC, BL Miller “Self-Selection in Olefin Cross-Metathesis: A Study on
the Effects of Remote Functionality” Org. Lett. 7, 733 (2005
48. N Ross, BR McNaughton, BL Miller “Combinatorial Chemistry in the Drug Discovery Process” Drug Discovery
Handbook, Wiley & Sons, Chapter 21 (2004)
49. BR McNaughton, BL Miller “A Mild and Efficient One-Step Synthesis of Quinolines” Org. Lett. 5, 4257 (2003)
CURRENT RESEARCH FUNDING
2022-27 NIH – Research Centers in Minority Institutions (RCMI) “Interdisciplinary Health Equity Research (IHER) Center”
Roles: PI for research project “Integrating Low-Cost Paper-Based Devices and
Personalized Immunotherapeutics to Treat Triple Negative Breast Cancer”
(1U54MD015959), and, Director: Investigator Development Core $1,432,750
2021-22 Delaware Biosciences Institute – Applied Research Collaborations (ARC) “Novel Immunotherapeutics Targeting PMSA-Positive Prostate Cancer” Role: PI $75,000
2021 INBRE Core Access Award Role: PI $4,000
2022-24 National Institutes of Health (NIGMS) “Evolved RNA Recognition Motifs for Therapeutic and Gene Editing Applications” (R15GM141783) Role: PI $438,000
COMPLETED RESEARCH FUNDING
2021 Delaware-CTR ACCEL – Shovel-Ready Pilot Grants Program (ShoRe PGP) “SARS- CoV-2 Entry Inhibitors as Therapeutics and Prophylaxis” Role: PI $29,000
2017 National Institutes of Health (NIGMS), “Cyclic Peptide Inhibitors of HIV-1 Proliferation” (R01GM123864) Role: co-PI $1,571,690
2016 Novartis, “Evolution of CUG Repeat RNA-Binding Proteins” Role: PI $50,000
2015 National Institutes of Health (NIGMS), “Protein Drug Leads That Target Challenging Protein or Nucleic Acid Structures” (R01MG107520, diversity supplement) Role: PI $21,346
2014 National Institutes of Health (NIGMS), “Protein Drug Leads That Target Challenging Protein or Nucleic Acid Structures” (R01MG107520)
Role: PI $1,489,900
2014 Coca-Cola Corporation, “Low-Cost Detection of Candidatus Liberibacter” Role: PI $80,000
2014 Colorado Center for Drug Discovery, “Inhibitors of HIV Entry” Role: PI $50,000
2012 Leukemia Research Foundation, “Overcoming Resistance to Chemotherapeutic Intervention in Leukemia” Role: PI $100,000
2012 Colorado Center for Drug Discovery, “Evolution of Gankyrin-Binding Proteins” Role: PI $50,000
2010 CSURF-CSU Ventures, “SAR Analysis of Novel Anti-Flaviviral Compounds” Role: co-PI $50,000
2010 DoD/CDMPR, “A Selection-Based Approach to Evolve Prostate Cancer-Selective Cell- Penetrating Peptides Role: PI $330,750